{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Volociximab",
  "nciThesaurus": {
    "casRegistry": "558480-40-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05)",
    "fdaUniiCode": "496K5Z02NW",
    "identifier": "C48426",
    "preferredName": "Volociximab",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C20401"
    ],
    "synonyms": [
      "Anti-alpha5-beta1 Integrin",
      "M200",
      "VOLOCIXIMAB",
      "Volociximab",
      "anti-a5-beta1 Integrin",
      "volociximab"
    ]
  }
}